China Resources Double-Crane PharmaceuticalLtd Past Earnings Performance
Past criteria checks 2/6
China Resources Double-Crane PharmaceuticalLtd has been growing earnings at an average annual rate of 8.4%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 4% per year. China Resources Double-Crane PharmaceuticalLtd's return on equity is 12.4%, and it has net margins of 13.1%.
Key information
8.4%
Earnings growth rate
8.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 4.0% |
| Return on equity | 12.4% |
| Net Margin | 13.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Oct 29
China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Low P/E No Reason For Excitement
Oct 21An Intrinsic Calculation For China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Suggests It's 49% Undervalued
Sep 30We Think China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) Can Manage Its Debt With Ease
Jul 16China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets
Mar 24Investors Don't See Light At End Of China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Tunnel
Mar 02Revenue & Expenses Breakdown
How China Resources Double-Crane PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 10,322 | 1,348 | 3,664 | 621 |
| 30 Jun 24 | 10,308 | 1,395 | 3,521 | 626 |
| 31 Mar 24 | 10,285 | 1,374 | 3,508 | 580 |
| 31 Dec 23 | 10,222 | 1,333 | 3,479 | 561 |
| 30 Sep 23 | 10,916 | 1,584 | 3,865 | 579 |
| 30 Jun 23 | 10,558 | 1,428 | 3,795 | 554 |
| 31 Mar 23 | 9,880 | 1,223 | 3,526 | 510 |
| 31 Dec 22 | 9,625 | 1,180 | 3,479 | 482 |
| 30 Sep 22 | 9,394 | 1,025 | 3,341 | 460 |
| 30 Jun 22 | 9,392 | 1,078 | 3,415 | 425 |
| 31 Mar 22 | 9,222 | 981 | 3,420 | 421 |
| 31 Dec 21 | 9,112 | 936 | 3,504 | 410 |
| 30 Sep 21 | 9,006 | 1,021 | 3,524 | 392 |
| 30 Jun 21 | 8,987 | 1,046 | 3,638 | 359 |
| 31 Mar 21 | 8,730 | 1,016 | 3,772 | 320 |
| 31 Dec 20 | 8,504 | 1,005 | 3,768 | 291 |
| 30 Sep 20 | 8,348 | 1,010 | 3,751 | 244 |
| 30 Jun 20 | 8,663 | 971 | 4,036 | 228 |
| 31 Mar 20 | 8,930 | 1,001 | 4,131 | 211 |
| 31 Dec 19 | 9,381 | 1,055 | 4,361 | 202 |
| 30 Sep 19 | 9,322 | 1,043 | 4,347 | 189 |
| 30 Jun 19 | 9,003 | 1,024 | 4,186 | 180 |
| 31 Mar 19 | 8,720 | 997 | 4,052 | 154 |
| 31 Dec 18 | 8,225 | 969 | 3,780 | 145 |
| 30 Sep 18 | 7,975 | 962 | 3,640 | 142 |
| 30 Jun 18 | 7,434 | 905 | 3,252 | 144 |
| 31 Mar 18 | 7,032 | 908 | 2,838 | 176 |
| 31 Dec 17 | 6,422 | 843 | 2,394 | 152 |
| 30 Sep 17 | 6,103 | 838 | 2,232 | 90 |
| 30 Jun 17 | 5,725 | 801 | 2,011 | 57 |
| 31 Mar 17 | 5,584 | 767 | 1,991 | 0 |
| 31 Dec 16 | 5,495 | 714 | 1,953 | 0 |
| 30 Sep 16 | 5,490 | 705 | 1,917 | 0 |
| 30 Jun 16 | 5,414 | 684 | 1,886 | 0 |
| 31 Mar 16 | 5,274 | 645 | 1,837 | 0 |
| 31 Dec 15 | 5,138 | 661 | 1,818 | 0 |
| 30 Sep 15 | 5,733 | 865 | 2,006 | 0 |
| 30 Jun 15 | 5,562 | 832 | 1,943 | 0 |
| 31 Mar 15 | 5,413 | 785 | 1,881 | 0 |
| 31 Dec 14 | 5,153 | 737 | 1,722 | 0 |
| 30 Sep 14 | 4,276 | 776 | 1,377 | 0 |
| 30 Jun 14 | 5,184 | 845 | 1,344 | 0 |
| 31 Mar 14 | 6,010 | 859 | 1,406 | 0 |
| 31 Dec 13 | 6,835 | 871 | 1,498 | 0 |
Quality Earnings: 600062 has high quality earnings.
Growing Profit Margin: 600062's current net profit margins (13.1%) are lower than last year (14.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600062's earnings have grown by 8.4% per year over the past 5 years.
Accelerating Growth: 600062's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 600062 had negative earnings growth (-14.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 600062's Return on Equity (12.4%) is considered low.